tag real-world-data 
pharmaphorum
AUGUST 28, 2020
The world is awash with data, and while retailers and TV subscription services have perfected the art of collection and curation, public health has been trailing behind. Data inadequacies. At this moment, people recognise that monitoring infectious diseases, in the US or globally, is challenging because data takes time.
pharmaphorum
DECEMBER 17, 2021
Aduhelm (aducanumab) was approved by the FDA in June, but has been held back by a glacial rollout as clinicians have questioned the data on which the decision to clear the drug was based, plus a $56,000 per year price tag, which has in turn led to pushback by payers.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
pharmaphorum
AUGUST 17, 2020
The financial world, like the pharmaceutical industry, must operate within a tightly-defined regulatory environment, and in doing so has proved adept at connecting with its customers. Utilising 3D animation, motion graphics, illustration and data visualisation, Mechanism of Action videos are created to visually explain drug or device impact.
pharmaphorum
JUNE 8, 2021
Dementia specialist Prof Robert Howard of University College London (UCL) was also damning in his assessment of the decision, saying that the FDA has “sidestepped available clinical trial outcomes data that indicate the drug probably doesn’t work.” Accelerated approval is probably a reasonable middle ground here.
Viseven
NOVEMBER 30, 2022
From AI-based drug discovery to running virtual cohorts for clinical trials or doing continuous manufacturing instead of batch manufacturing, from launching a project effectively to doing real-world tickets, there is technology penetration all along the value chain. We see many opportunities across the value chain.
pharmaphorum
NOVEMBER 28, 2022
Substra is the software that powered the MELLODDY platform, a collaboration in which Amgen, Astellas, AstraZeneca, Bayer, Boehringer Ingelheim, GSK, Janssen, Merck, Novartis, and Servier all agreed to share drug discovery data — but not with each other directly, nor with Owkin. Open source is undoubtedly the future of AI research.”.
Pharmaceutical Technology
JANUARY 27, 2023
Over the last few years, as price tags for drugs have continuously increased, the popularity of risk sharing agreements has been increasing at a rate of 24% annual average growth. Furthermore, he said extracting data to validate the criteria for a warranty reimbursement could be an onerous process.
Expert insights. Personalized for you.
64 
Let's personalize your content